A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
INNATE PHARMA operates in the Biotechnology industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 56M | 52M | - | 64M |
| Net Income | -53M | -53M | -8.2M | -61M | -62M | -73M |
| EPS | $-0.66 | $-0.66 | $-0.10 | $-0.77 | $-0.78 | $-0.93 |
| Free Cash Flow | -7.9M | -7.9M | -36M | -21M | -70M | -60M |
| ROIC | -36.7% | -36.7% | -86.3% | -450.3% | -137.0% | - |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 2.52 | 0.60 | 0.74 | 0.13 | 0.11 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -56M | -56M | -14M | -60M | -56M | - |
| Operating Margin | 0.0% | - | -24.4% | -115.8% | - | - |
| ROE | -560.0% | -162.2% | -14.5% | -66.6% | -40.7% | -34.8% |
| Shares Outstanding | 81M | 81M | 84M | 80M | 80M | 79M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 77M | 64M | N/A | 52M | 56M | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | -88M | -57M | -55M | -54M | -61M | -56M | -56M |
| SG&A | -29M | -22M | -30M | -24M | -20M | -21M | -21M |
| EBIT | -30M | N/A | -56M | -60M | -14M | -56M | -56M |
| Op. Margin | -39.2% | N/A | N/A | -115.8% | -24.4% | N/A | 0.0% |
| Net Income | -23M | -73M | -62M | -61M | -8.2M | -53M | -53M |
| Net Margin | -30.1% | -113.9% | N/A | -117.2% | -14.6% | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | -65.2% | N/A | -137.0% | N/M | -86.3% | -36.7% | -36.7% |
| ROE | -9.5% | -34.8% | -40.7% | -66.6% | -14.5% | -162.2% | -560.0% |
| ROA | -5.2% | -18.3% | -18.6% | -22.9% | -4.0% | -34.5% | -44.5% |
| Cash Flow | |||||||
| Op. Cash Flow | 39M | -59M | -69M | -20M | -35M | -7.5M | -7.5M |
| Free Cash Flow | 38M | -60M | -70M | -21M | -36M | -7.9M | -7.9M |
| Owner Earnings | 16M | -128M | -77M | -72M | -40M | -12M | -12M |
| CapEx | 1.4M | 1.0M | 1.1M | 563K | 381K | 422K | 422K |
| Maint. CapEx | 18M | 65M | 5.4M | 48M | 0 | 0 | 0 |
| Growth CapEx | 0 | 0 | 0 | 0 | N/A | N/A | 422K |
| D&A | 18M | 65M | 5.4M | 48M | 0 | 0 | 0 |
| CapEx/OCF | 3.6% | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 4.3M | 2.8M | 3.1M | 4.5M | 4.6M | 4.3M | 4.3M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | -208M | -138M | -106M | -46M | -43M | -48M | -72M |
| Cash & Equiv. | 227M | 157M | 122M | 89M | 77M | 72M | 72M |
| Long-Term Debt | 19M | 19M | 16M | 42M | 34M | 24M | 24M |
| Debt/Equity | 0.08 | 0.11 | 0.13 | 0.74 | 0.60 | 2.52 | 0.00 |
| Interest Coverage | -5.4 | N/A | -12.0 | -10.8 | -6.9 | -13.0 | -13.0 |
| Equity | 243M | 179M | 127M | 57M | 56M | 9.5M | 9.5M |
| Total Assets | 449M | 353M | 316M | 219M | 190M | 120M | 120M |
| Total Liabilities | 206M | 174M | 189M | 162M | 134M | 110M | 110M |
| Intangibles | N/A | N/A | N/A | N/A | 452K | 0 | 0 |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Working Capital | 130M | 147M | 69M | 104M | 118M | 57M | 57M |
| Current Assets | 266M | 199M | 163M | 147M | 161M | 93M | 93M |
| Current Liabilities | 136M | 52M | 94M | 44M | 43M | 36M | 36M |
| Per Share Data | |||||||
| EPS | -0.35 | -0.93 | -0.78 | -0.77 | -0.10 | -0.66 | -0.66 |
| Owner EPS | 0.24 | -1.61 | -0.97 | -0.91 | -0.48 | -0.14 | -0.14 |
| Book Value | 3.63 | 2.27 | 1.58 | 0.72 | 0.67 | 0.12 | 0.12 |
| Cash Flow/Share | 0.58 | -0.75 | -0.86 | -0.25 | -0.42 | -0.09 | -0.66 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 67.0M | 79.0M | 80.0M | 79.6M | 84.1M | 81.1M | 81.1M |
| Valuation | |||||||
| P/E Ratio | -19.0 | -4.7 | -6.4 | -2.9 | -29.6 | -3.1 | -1.8 |
| P/FCF | 11.7 | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 1.8 | 1.9 | 3.1 | 3.1 | 4.3 | 17.2 | 10.2 |
| Price/Sales | 5.7 | 5.4 | N/A | 3.4 | 4.3 | N/A | N/A |
| FCF Yield | 8.6% | -17.4% | -17.7% | -11.8% | -14.7% | -4.8% | -8.1% |
| Market Cap | 440M | 347M | 396M | 175M | 244M | 165M | 97M |
| Avg. Price | 6.91 | 5.86 | 4.50 | 2.95 | 3.00 | 2.25 | 1.20 |
| Year-End Price | 6.58 | 4.39 | 4.95 | 2.20 | 2.90 | 2.03 | 1.20 |
INNATE PHARMA passes 1 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is -11.7%.
INNATE PHARMA (IPH-PA) has a 5-year average return on invested capital (ROIC) of -86.7%. This is below average and may indicate limited pricing power.
INNATE PHARMA (IPH-PA) has a market capitalization of $97M. It is classified as a small-cap stock.
INNATE PHARMA (IPH-PA) does not currently pay a regular dividend.
INNATE PHARMA (IPH-PA) operates in the Biotechnology industry, within the Healthcare sector.
INNATE PHARMA (IPH-PA) generated $-8 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
INNATE PHARMA (IPH-PA) has a debt-to-equity ratio of 2.52. This indicates higher leverage, which may increase financial risk.
INNATE PHARMA (IPH-PA) reported earnings per share (EPS) of $-0.66 in its most recent fiscal year.
INNATE PHARMA (IPH-PA) has a return on equity (ROE) of -162.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 6 years of financial data for INNATE PHARMA (IPH-PA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
INNATE PHARMA (IPH-PA) has a book value per share of $0.12, based on its most recent annual SEC filing.